Document Detail

Alternative transplant donor sources: is there any consensus?
MedLine Citation:
PMID:  23385861     Owner:  NLM     Status:  In-Data-Review    
PURPOSE OF REVIEW: To review the data supporting the use of alternative donors for hematopoietic cell transplantation of patients with high-risk or advanced hematological malignancies.
RECENT FINDINGS: Advances in supportive therapy and technology have improved the safety and efficacy of alternative donors for hematopoietic cell transplantation. Molecular techniques have allowed for better human leukocyte antigen matching of unrelated adult donors. Novel strategies such as adoptive regulatory T cells or posttransplantation cyclophosphamide contributed to better outcomes after partially matched related donors. In umbilical cord blood transplantation, the ability to find adequately dosed single-unit grafts, the utilization of double-unit grafts, and novel methodologies such as ex-vivo expansion, intrabone injection, and priming to accelerate engraftment are promising. Available retrospective studies suggest despite the differences in hematopoietic recovery, risk of graft-versus-host disease, and relapse, long-term outcomes are similar between different alternative donor types.
SUMMARY: In the absence of a suitable matched related donor, most patients will be able to find an alternative donor to proceed to a potentially curative allogeneic transplantation. Emerging new technologies will further improve the safety and efficacy of alternative donor transplantation. Ongoing and future randomized studies will better define the relative efficacy of alternative donor types.
Ephraim Fuchs; Paul V O'Donnell; Claudio G Brunstein
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in oncology     Volume:  25     ISSN:  1531-703X     ISO Abbreviation:  Curr Opin Oncol     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007265     Medline TA:  Curr Opin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  173-9     Citation Subset:  IM    
aBlood and Marrow Transplantation Programs, Johns Hopkins University, Baltimore, Maryland bFred Hutchinson Cancer Research Center, Seattle, Washington cUniversity of Minnesota, Minneapolis, Minnesota, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.
Next Document:  Hematopoietic stem cell transplantation in HIV-1-infected individuals: clinical challenges and the ...